An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Human skin replacement (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; First in man
- Sponsors Stratatech
- 14 Feb 2018 According to a Mallinckrodt media release, the first patient has been enrolled in this trial.
- 26 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 26 Jan 2018 Planned primary completion date changed from 1 Apr 2019 to 1 May 2019.